SCHEMBL6444357

SCHEMBL6444357

Cc1cnc(COc2nc(N)nc(-c3ccccn3)c2C#N)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 6/20 0.37
ADORA2A P29274 2/20 0.37
ADORA1 P30542 2/20 0.37
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
GLA P06280 2/20 0.36
GAA P10253 2/20 0.36
HPGD P15428 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.36
GRM5 P41594 1/20 0.36
PIK3CD O00329 4/20 0.35
FFAR1 O14842 2/20 0.35
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6443034 0.88 SQOR (0.41) SQORADORA2AADORA1KDM4ENPC1
SCHEMBL6441608 0.84 ADORA2A (0.41) SQORADORA2AADORA1KDM4EALDH1A1
SCHEMBL5131946 0.81 ADORA2A (0.48) ADORA2AADORA1KDM4EALDH1A1GLA
SCHEMBL5139992 0.80 KDM4E (0.39) ADORA2AADORA1KDM4EALDH1A1GLA
SCHEMBL6443675 0.80 MGMT (0.48) SQORADORA2AADORA1KDM4EALDH1A1
SCHEMBL6441081 0.78 POLB (0.37) ADORA2AADORA1KDM4EALDH1A1GLA
SCHEMBL7151940 0.77 SQOR (0.55) SQORADORA2AADORA1KDM4EPIK3CD
SCHEMBL6442327 0.77 HSP90AA1 (0.33) ALDH1A1POLB
SCHEMBL6442933 0.75 ADORA2A (0.42) SQORADORA2AADORA1KDM4EALDH1A1
3-Methylpyridine SCHEMBL7499123 0.74 SQOR (0.46) SQORADORA2AADORA1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 SQOR 798/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.